Rivaroxaban Use for Thrombosis Prophylaxis Is Associated With Early Periprosthetic Joint Infection

Journal of Arthroplasty

Volumn 31, Issue 6, 2016, Pages 1295-1298

  Brimmo, Olubusola ^a   Glenn, Margaret ^a   Klika, Alison K ^a   Murray, Trevor G ^a   Molloy, Robert M ^a   Higuera, Carlos A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Periprosthetic joint infection; Rivaroxaban; Thromboprophylaxis; Total hip arthroplasty; Total knee arthroplasty

Indexed keywords

ACETYLSALICYLIC ACID; DABIGATRAN; ENOXAPARIN; HEPARIN; RIVAROXABAN; WARFARIN; ANTICOAGULANT AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; INCIDENCE; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; PERIPROSTHETIC JOINT INFECTION; SURGICAL INFECTION; THROMBOSIS PREVENTION; TOTAL HIP PROSTHESIS; TOTAL KNEE ARTHROPLASTY; TREATMENT OUTCOME; ADVERSE EFFECTS; AGED; ARTHRITIS, INFECTIOUS; COMMUNITY HOSPITAL; HIP PROSTHESIS; HIP REPLACEMENT; KNEE PROSTHESIS; KNEE REPLACEMENT; MIDDLE AGED; POSTOPERATIVE PERIOD; RETROSPECTIVE STUDY; RISK FACTOR; SEVERITY OF ILLNESS INDEX; SURGICAL WOUND INFECTION; VENOUS THROMBOSIS;

AGED; ANTICOAGULANTS; ARTHRITIS, INFECTIOUS; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; FEMALE; HIP PROSTHESIS; HOSPITALS, COMMUNITY; HUMANS; INCIDENCE; KNEE PROSTHESIS; MALE; MIDDLE AGED; POSTOPERATIVE PERIOD; RETROSPECTIVE STUDIES; RISK FACTORS; RIVAROXABAN; SEVERITY OF ILLNESS INDEX; SURGICAL WOUND INFECTION; VENOUS THROMBOSIS;

EID: 84954286576     PISSN: 08835403     EISSN: 15328406     Source Type: Journal    
DOI: 10.1016/j.arth.2015.12.027     Document Type: Article

References (27)

1. Lidgren L. Joint prosthetic infections: a success story. Acta Orthop Scand 2001, 72:553.
2. Phillips J.E., Crane T.P., Noy M., et al. The incidence of deep prosthetic infections in a specialist orthopaedic hospital: a 15-year prospective survey. J Bone Joint Surg Br 2006, 88:943.
3. Darouiche R.O. Treatment of infections associated with surgical implants. N Engl J Med 2004, 350:1422.
4. Kurtz S.M., Lau E., Schmier J., et al. Infection burden for hip and knee arthroplasty in the United States. J Arthroplasty 2008, 23:984.
5. Geerts W.H., Bergqvist D., Pineo G.F., et al. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008, 133(6 Suppl):381S.
6. Press Announcements - FDA expands use of Xarelto to treat, reduce recurrence of blood clots n.d. [accessed 13.04.14]. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm326654.htm.
7. Eriksson B.I., Borris L.C., Friedman R.J., et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008, 358:2765.
8. Kakkar A.K., Brenner B., Dahl O.E., et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008, 372:31.
9. Lassen M.R., Ageno W., Borris L.C., et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008, 358:2776.
10. Turpie A.G.G., Lassen M.R., Davidson B.L., et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009, 373:1673.
11. Lotke P.A. Rivaroxaban for thromboprophylaxis. N Engl J Med 2008, 359:2174. author reply 2175-2176.
12. Jensen C.D., Steval A., Partington P.F., et al. Return to theatre following total hip and knee replacement, before and after the introduction of rivaroxaban: a retrospective cohort study. J Bone Joint Surg Br 2011, 93:91.
13. Chahal G.S., Saithna A., Brewster M., et al. A comparison of complications requiring return to theatre in hip and knee arthroplasty patients taking enoxaparin versus rivaroxaban for thromboprophylaxis. Ortop Traumatol Rehabil 2013, 15:125.
14. Charlson M.E., Pompei P., Ales K.L., et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40:373.
15. Samama M.M. The mechanism of action of rivaroxaban-an oral, direct factor Xa inhibitor-compared with other anticoagulants. Thromb Res 2011, 127:497.
16. Byrne A.M., Morris S., McCarthy T., et al. Outcome following deep wound contamination in cemented arthroplasty. Int Orthop 2007, 31:27.
17. Sindali K., Rose B., Soueid H., et al. Elective hip and knee arthroplasty and the effect of rivaroxaban and enoxaparin thromboprophylaxis on wound healing. Eur J Orthop Surg Traumatol 2013, 23:481.
18. Lehtimäki M.Y., Kautiainen H., Lehto U.K., et al. Charnley low-friction arthroplasty in rheumatoid patients: a survival study up to 20 years. J Arthroplasty 1999, 14:657.
19. Fender D., Harper W.M., Gregg P.J. Outcome of Charnley total hip replacement across a single health region in England: the results at five years from a regional hip register. J Bone Joint Surg Br 1999, 81:577.
20. Jameson S.S., Rymaszewska M., Hui A.C.W., et al. Wound complications following rivaroxaban administration: a multicenter comparison with low-molecular-weight heparins for thromboprophylaxis in lower limb arthroplasty. J Bone Joint Surg Am 2012, 94:1554.
21. Lassen M.R., Gent M., Kakkar A.K., et al. The effects of rivaroxaban on the complications of surgery after total hip or knee replacement: results from the RECORD programme. J Bone Joint Surg Br 2012, 94:1573.
22. Maderazo E.G., Judson S., Pasternak H. Late infections of total joint prostheses. A review and recommendations for prevention. Clin Orthop 1988, 131.
23. Peersman G., Laskin R., Davis J., et al. Infection in total knee replacement: a retrospective review of 6489 total knee replacements. Clin Orthop 2001, 15.
24. Winiarsky R., Barth P., Lotke P. Total knee arthroplasty in morbidly obese patients. J Bone Joint Surg Am 1998, 80:1770.
25. Lazzarini L., Pellizzer G., Stecca C., et al. Postoperative infections following total knee replacement: an epidemiological study. J Chemother Florence Italy 2001, 13:182.
26. Berbari E.F., Hanssen A.D., Duffy M.C., et al. Risk factors for prosthetic joint infection: case-control study. Clin Infect Dis 1998, 27:1247.
27. McCullagh L., Tilson L., Walsh C., et al. A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the Irish healthcare setting. PharmacoEconomics 2009, 27:829.